• Fisher & Paykel shares have given a return of 23.4% in 6 months and last traded at $34.90 on 8 October, up by 3.90%.
  • Hospital hardware sales grew by 390%, hospital consumables revenue rose by 48% and overall Hospital product group revenue increased by 91% during Apr-Jul 2020.
  • The Company expects operating revenue of $1.61 billion and NPAT of $365 million to $385 million for 2021.
  • FPH has started with the planning of its 3rd manufacturing facility in Mexico, which is to be authorised within the next 2 years.

Healthcare companies have witnessed increased investors’ interest, as they persistently try to discover a vaccine and control the spread of coronavirus. Healthcare stocks can prove to be a sound investment amid these challenging times of coronavirus, as a prospective remedy to cure the virus can result in enormous gains for the stock.

Let’s have a look at the performance of Fisher & Paykel healthcare shares.

ALSO READ: Healthcare Sector Supported Gain in S&P/NZX50

Fisher & Paykel share price ended the trading session at $34.90 on 8 October, up 3.90% from the previous close. In the past one month, FPH stock has given a return of 3.25%, while it has increased by 23.32% in the past 6 months.

On 9 October, Fisher &Paykel share price was at $34.55, marginally up by 0.32%.

Fisher & Paykel Healthcare Corporation Ltd (NZX:FPH) is a prominent designer, manufacturer and seller of products and systems utilised in chronic respiratory care, surgery and treatment of sleep apnea.


Key Highlights

Fisher & Paykel has witnessed robust demand for its hospital respiratory care products for the first 4 months to the end of July 2020 amid COVID-19.

Last month, Fisher & Paykel provided a trading update for the initial four months of FY21.

Some of the highlights of FY21 trading update includes of the following:

  • During the four-month period, hospital hardware sales have witnessed a surge, with 390% constant currency revenue growth over the first four months of FY21 compared to pcp
  • Hospital consumables revenue and overall hospital product group revenue have grown by 48% and 91% on pcp, respectively from April-July 2020
  • International sales of both invasive ventilation and optiflow consumables in July have reverted to levels seen in April
  • Revenue has been impacted by the magnitude of COVID-19 spread in a particular region, with above 50% of the Company’s Airvo hardware sales occurring outside North America and Europe 
  • Homecare revenue rose by 5% in July end, in constant currency terms, compared to pcp

The Company also intends to launch its third manufacturing facility in Mexico, which is to be authorised within next 2 years. The healthcare firm is continuing to increase its manufacturing capacity to make sure that a further rise in the supply of its respiratory products is accessible when required.

FY21 Outlook 

Fisher & Paykel also updated its previous assumptions (announced in June) due to substantial uncertainty arising from COVID-19. 

The Company expects global hospitalisations requiring respiratory support to return to normal by the end of 2020. It has also maintained an expectation of lower OSA diagnosis rate.

ALSO READ: Is Fisher & Paykel Healthcare Share Price Still a Buy Post Raising its Guidance

The full-year operating revenue for the financial year of 2021 is expected to be about $1.61 billion, and NPAT will be nearly $365 million to $385 million.

 (NOTE: Currency is reported in NZ Dollar unless stated otherwise)


Perception around gold has been undergoing a paradigm shift and is now seen as a crucial strategic asset, with changing macroeconomic conditions. A vibrant gold market has a positive impact on companies that are involved in the exploration and mining activities.



The website is a service of Kalkine Media New Zealand Limited (Company Number 8107196).The article has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. The above article is NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) or engage in any investment activity under discussion.Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. We are neither licensed nor qualified to provide investment advice through this platform.


We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK